Back to LLYView Full Landscape
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
10 competitors in Alzheimer Disease
SAVASimufilam
Phase 3SNYxaliproden (SR57746A)
Phase 3BIIBBIIB080
Phase 2SNYAVE1625
Phase 2NRSNPrimeC
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/24/2025
Kisunla
Donanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology (see section 4.4).
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
